All In Biotech

Drug Trial Radar · NCT00421889

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Jul 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Aug 2005

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
Valerio TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.

Conditions

  • Ovarian Cancer
  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Bladder Cancer

Interventions

  • belinostatDrug

  • PaclitaxelDrug

  • CarboplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerable Dose (MTD) Belinostat, Part A,Time frame: Cycle 1
  2. Dose Limiting Toxicities (DLT), Part ATime frame: Cycle 1

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Gynecologic Oncology Associates

    Newport Beach, California

  • Research Facility

    Orlando, Florida

  • Hematology and Oncology Specialists, LLC

    Covington, Louisiana

  • Hematology & Oncology Specialists, LLC

    Metairie, Louisiana

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Women & Infants Hospital of Rhode Island

    Providence, Rhode Island

  • The Finsen Center, Rigshospitalet

    Copenhagen, Denmark

  • Research Facility, Herlev University Hospital

    Herlev, Denmark

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • The Royal Marsden NHS Trust

    Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.